1-8 of 8
Xin Yu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B079: Molecular determinants of sensitivity to Polatuzumab-Vedotin

Sean R Corcoran, Jaewoo Choi, Rachel E Fenner, Xin Yu, Sebastian Scheich, Galina Schevchenko, Evangelia K Papachristou, Vivian M Morris, Kamal Kishore, Clive S D'Santos, Stefania Pittaluga, George Wright, Jagan Muppidi, Daniel J Hodson, Louis M Staudt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B079.
https://doi.org/10.1158/1535-7163.TARG-23-B079
Published: 01 December 2023
View article titled, Abstract B079: Molecular determinants of sensitivity to Polatuzumab-Vedotin
Journal Articles

Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology

Jia Xin Yu, Amanda J. Craig, Mary E. Duffy, Carlos Villacorta-Martin, Verónica Miguela, Marina Ruiz de Galarreta, Alexander P. Scopton, Lisa Silber, Andres Y. Maldonado, Alexander Rialdi, Ernesto Guccione, Amaia Lujambio, Augusto Villanueva, Arvin C. Dar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (9): 1506–1519.
https://doi.org/10.1158/1535-7163.MCT-18-0571
Published: 03 September 2019
View article titled, Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology
Open the PDF for Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology in another window
Includes: Supplementary data
Journal Articles

Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding

Saif Zaman, Xin Yu, Anthony F. Bencivenga, Adam R. Blanden, Yue Liu, Tracy Withers, Bing Na, Alan J. Blayney, John Gilleran, David A. Boothman, Stewart N. Loh, S. David Kimball, Darren R. Carpizo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (8): 1355–1365.
https://doi.org/10.1158/1535-7163.MCT-18-1080
Published: 01 August 2019
View article titled, Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding
Open the PDF for Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding in another window
Includes: Supplementary data
Journal Articles

Abstract B211: Cellular zinc homeostatic mechanisms function as an off switch for zinc metallochaperone-mediated reactivation of mutant p53

Xin Yu, Samuel Kogan, Ying Chen, Ashley T. Tsang, Tracy Withers, Hongxia Lin, Chunxia Chen, Dirk F. Moore, Joseph Bertino, Chang Chan, Darren R. Carpizo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B211.
https://doi.org/10.1158/1535-7163.TARG-17-B211
Published: 01 January 2018
View article titled, Abstract B211: Cellular zinc homeostatic mechanisms function as an off switch for zinc metallochaperone-mediated reactivation of mutant p53
Journal Articles

U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts

Ashley T. Tsang, Crissy Dudgeon, Lan Yi, Xin Yu, Rafal Goraczniak, Kristen Donohue, Samuel Kogan, Mark A. Brenneman, Eric S. Ho, Samuel I. Gunderson, Darren R. Carpizo
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (8): 1445–1455.
https://doi.org/10.1158/1535-7163.MCT-16-0867
Published: 02 August 2017
View article titled, U1 Adaptors Suppress the <em>KRAS-MYC</em> Oncogenic Axis in Human Pancreatic Cancer Xenografts
Open the PDF for U1 Adaptors Suppress the <em>KRAS-MYC</em> Oncogenic Axis in Human Pancreatic Cancer Xenografts in another window
Includes: Supplementary data
Journal Articles

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer

Ming-Wu Zheng, Chun-Hui Zhang, Kai Chen, Mei Huang, Ya-Ping Li, Wan-Ting Lin, Rong-Jie Zhang, Lei Zhong, Rong Xiang, Lin-Li Li, Xin-Yu Liu, Yu-Quan Wei, Sheng-Yong Yang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (3): 366–378.
https://doi.org/10.1158/1535-7163.MCT-15-0501
Published: 06 March 2016
View article titled, Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer
Open the PDF for Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects

Qie Guo, Peixiang Lan, Xin Yu, Qiuju Han, Jian Zhang, Zhigang Tian, Cai Zhang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (6): 1503–1513.
https://doi.org/10.1158/1535-7163.MCT-13-0722
Published: 04 June 2014
View article titled, Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects
Open the PDF for Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects in another window
Includes: Supplementary data
Journal Articles

Abstract A121: Novel PARP inhibitors with potent antitumor activity as single‐agent and combination therapies

Bing Wang, Daniel Chu, Ying Feng, Xin Yu, Peter Myers, Leonard Post, Yuqiao (Jerry) Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A121.
https://doi.org/10.1158/1535-7163.TARG-09-A121
Published: 10 December 2009
View article titled, Abstract A121: Novel PARP inhibitors with potent antitumor activity as single‐agent and combination therapies